XBiotech, Inc.

As of November 9, 2023, XBiotech, Inc. is considered overvalued with a valuation grade of "does not qualify," showing significant financial deterioration, highlighted by a negative P/E ratio of -2.0190, negative returns on equity of -22.56%, and a year-to-date stock performance of -34.43% compared to the S&P 500's 2.44%.

As of June 11, 2025, XBiotech, Inc. has a bearish technical outlook, supported by bearish daily moving averages, monthly MACD, and Bollinger Bands, despite a mildly bullish weekly MACD and KST.

As of March 2022, the management team of XBiotech, Inc. includes John Simard as Chairman, President, CEO, and Founder, with Jan-Paul Waldin as Lead Independent Director and Peter Libby, Donald MacAdam, and W. Thorpe McKenzie as Independent Directors.

XBiotech, Inc. is a clinical-stage biopharmaceutical company focused on developing True Human monoclonal antibodies for various diseases. It has a market cap of $79.57 million and reported a net profit loss of $11 million as of March 2025.

As of Jun 18, XBiotech, Inc. has a market capitalization of 79.57 million, classifying it as a Micro Cap company, with net sales of 0.00 million and a net profit of -39.41 million over the latest four quarters. The company reported shareholder's funds of 182.27 million and total assets of 199.09 million as of Dec 24.